Total Payments
$1,159
2024 Payments
$48.87
Companies
6
Transactions
19
Medicare Patients
367
Medicare Billing
$40,001
Payment Breakdown by Category
Food & Beverage$1,159 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,159 | 19 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $427.66 | 6 | $0 (2020) |
| Allergan Inc. | $271.28 | 5 | $0 (2019) |
| Theravance Biopharma Inc. | $245.11 | 2 | $0 (2017) |
| DePuy Synthes Sales Inc. | $144.57 | 3 | $0 (2023) |
| ABBVIE INC. | $48.87 | 2 | $0 (2024) |
| ViiV Healthcare Company | $21.58 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48.87 | 2 | ABBVIE INC. ($48.87) |
| 2023 | $144.57 | 3 | DePuy Synthes Sales Inc. ($144.57) |
| 2020 | $46.07 | 2 | Merck Sharp & Dohme Corporation ($24.49) |
| 2019 | $129.97 | 2 | Merck Sharp & Dohme Corporation ($65.58) |
| 2018 | $181.98 | 4 | Allergan Inc. ($101.89) |
| 2017 | $607.61 | 6 | Merck Sharp & Dohme Corporation ($257.50) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/23/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/16/2023 | DePuy Synthes Sales Inc. | ATTUNE (Device) | Food and Beverage | In-kind items and services | $135.70 | General |
| Category: Ortho-Knee | ||||||
| 03/16/2023 | DePuy Synthes Sales Inc. | ATTUNE (Device) | Food and Beverage | In-kind items and services | $3.11 | General |
| Category: Ortho-Knee | ||||||
| 03/02/2023 | DePuy Synthes Sales Inc. | ATTUNE (Device) | Food and Beverage | In-kind items and services | $5.76 | General |
| Category: Ortho-Knee | ||||||
| 10/06/2020 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/17/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: HIV | ||||||
| 11/13/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $64.39 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/15/2019 | Merck Sharp & Dohme Corporation | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $65.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/28/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/21/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/11/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $80.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/18/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $63.27 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/26/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/20/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $106.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $73.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/12/2017 | Theravance Biopharma Inc. | — | Food and Beverage | In-kind items and services | $143.99 | General |
| 03/15/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $101.12 | General |
| Category: Infectious Disease | ||||||
| 02/15/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $76.69 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 122 | 154 | $45,646 | $12,008 |
| 2022 | 3 | 94 | 156 | $42,694 | $11,161 |
| 2021 | 3 | 92 | 119 | $29,494 | $10,234 |
| 2020 | 3 | 59 | 71 | $18,188 | $6,598 |
Total Patients
367
Total Services
500
Medicare Billing
$40,001
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 41 | 43 | $17,372 | $4,335 | 25.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 61 | $13,054 | $3,744 | 28.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 27 | $8,343 | $2,493 | 29.9% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 23 | 23 | $6,877 | $1,437 | 20.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 100 | $21,400 | $5,573 | 26.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 41 | 42 | $16,968 | $4,461 | 26.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 14 | $4,326 | $1,127 | 26.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 68 | $11,224 | $3,871 | 34.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 31 | 33 | $10,098 | $3,508 | 34.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $8,172 | $2,855 | 34.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 20 | 22 | $6,676 | $2,444 | 36.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $5,808 | $2,113 | 36.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 26 | 36 | $5,704 | $2,041 | 35.8% |
About Robin Hampton
Robin Hampton is a Infectious Disease healthcare provider based in Williamsport, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720055940.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robin Hampton has received a total of $1,159 in payments from pharmaceutical and medical device companies, with $48.87 received in 2024. These payments were reported across 19 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($1,159).
As a Medicare-enrolled provider, Hampton has provided services to 367 Medicare beneficiaries, totaling 500 services with total Medicare billing of $40,001. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Williamsport, PA
- Active Since 03/07/2006
- Last Updated 05/24/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1720055940
Products in Payments
- ZERBAXA (Drug) $263.72
- AVYCAZ (Drug) $195.03
- ATTUNE (Device) $144.57
- DALVANCE (Drug) $125.12
- VIBATIV (Drug) $101.12
- DIFICID (Drug) $98.36
- DELSTRIGO (Drug) $65.58
- DOVATO (Drug) $21.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.